Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION phase 3 study of delandistrogene moxeparvovec in ambulatory and non-ambulatory males with Duchenne muscular dystrophy
MOH_2024-04-17_013317Phase 3Not yet recruiting
- Sponsor
- Sarepta Therapeutics
- Start
- Sep 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Delandistrogene moxeparvovec with Placebo (2 arms). Planned start Sep 2022; status: not yet recruiting.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2024-04-17_013317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-17_013317.